Cancer Genetics (CGIX) versus Its Rivals Critical Contrast

Cancer Genetics (NASDAQ:CGIX – Get Free Report) is one of 48 publicly-traded companies in the “Medical Laboratories” industry, but how does it compare to its rivals? We will compare Cancer Genetics to related businesses based on the strength of its institutional ownership, valuation, profitability, earnings, dividends, risk and analyst recommendations.

Risk and Volatility

Cancer Genetics has a beta of 2.72, suggesting that its share price is 172% more volatile than the S&P 500. Comparatively, Cancer Genetics’ rivals have a beta of 1.00, suggesting that their average share price is 0% more volatile than the S&P 500.

Get Cancer Genetics alerts:

Valuation and Earnings

This table compares Cancer Genetics and its rivals top-line revenue, earnings per share (EPS) and valuation.

Cancer Genetics’ rivals have higher revenue, but lower earnings than Cancer Genetics. Cancer Genetics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

8.9% of Cancer Genetics shares are held by institutional investors. Comparatively, 44.9% of shares of all “Medical Laboratories” companies are held by institutional investors. 15.0% of Cancer Genetics shares are held by company insiders. Comparatively, 21.6% of shares of all “Medical Laboratories” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations and price targets for Cancer Genetics and its rivals, as provided by MarketBeat.com.

As a group, “Medical Laboratories” companies have a potential upside of 41.02%. Given Cancer Genetics’ rivals higher probable upside, analysts clearly believe Cancer Genetics has less favorable growth aspects than its rivals.

Profitability

This table compares Cancer Genetics and its rivals’ net margins, return on equity and return on assets.

Summary

Cancer Genetics beats its rivals on 5 of the 9 factors compared.

Cancer Genetics Company Profile

(Get Free Report)

Vyant Bio, Inc. is a biotechnology company, which engages in drug discovery for complex neurodevelopmental and neurodegenerative disorders. The firm’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. Its programs are focused on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome, CDKL5 Deficiency Disorders, and familial Parkinson’s Disease. The company was founded on April 8, 1999 and is headquartered in Cherry Hill, NJ.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.